Global Leading Market Research Publisher Global Info Research announces the release of its latest report *“Fishing Medicines – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.* Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fishing Medicines market, including market size, share, demand, industry development status, and forecasts for the next few years.
For aquaculture farmers raising fish, shrimp, mollusks, and aquatic plants, disease outbreaks (bacterial, viral, parasitic) and poor water quality can cause catastrophic losses (30-70% mortality in severe episodes). Fishing medicine (fishery medicine) is a type of veterinary medicine specifically for aquatic species. Most fishery drugs are transplanted from human drugs, livestock/poultry drugs, and pesticides, with a small number being special drugs for aquatic products. They are categorized into water disinfectants, oral antimicrobials, parasite repellents, Chinese herbal medicines, biological products (vaccines, probiotics), water quality improvers, and others. The healthy development of fishery farming requires the support of fishery drugs, as fish may suffer from various diseases and adverse environmental effects during the breeding process. These drugs effectively prevent and treat diseases, improving breeding efficiency and production.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985164/fishing-medicines
Market Valuation & Growth Trajectory (2026-2032)
The global market for Fishing Medicines was estimated to be worth approximately US$ 1.85 billion in 2025 and is projected to reach US$ 2.45 billion by 2032, growing at a CAGR of 4.1% from 2026 to 2032 (Source: Global Info Research, 2026 revision). This growth reflects intensification of aquaculture (higher stocking densities increasing disease risk), rising global seafood demand (aquaculture surpasses wild capture), and stricter food safety regulations limiting antibiotic residues (driving innovation in vaccines, probiotics, herbal medicines). Major consumption regions: Asia-Pacific (China, India, Vietnam, Indonesia, Thailand, Bangladesh >70% of global aquaculture), Latin America (Ecuador, Brazil, Chile – shrimp, salmon), Europe (Norway, Scotland – salmon), North America (US, Canada – catfish, trout, shrimp).
Exclusive Observer Insights (Q1-Q2 2026): Key market trends include: (1) shift from antibiotics to vaccines (especially in salmon, trout); (2) growth of probiotics and immunostimulants (reducing disease pressure without drugs); (3) Chinese herbal medicines gaining acceptance (ban on antibiotic growth promoters in China animal feed, 2020; fish following); (4) water quality improvers (probiotics, enzymes, bioremediation) replacing chemical disinfectants in some systems (biofloc, RAS). Antimicrobial resistance (AMR) is major concern; US FDA limits antibiotic use in food fish (only approved drugs with withdrawal periods). Europe stricter. Asia has less regulation, leading to higher antibiotic consumption and resistance.
Key Market Segments: By Type, Application, and Species
Major players include BHUVAN BIOLOGICALS (India), NT Labs (UK, ornamental fish), 3 Little Fish (ornamental), Henan Chuangxin Biological Technology (China), Syndel (Canada, salmon aquaculture), Zoetis (US, global animal health major, fish vaccines, antibiotics), Veterquimica S.A. (Chile, salmon), HIPRA (Spain, aquaculture vaccines), Anicon Labor GmbH (Germany, diagnostic reagents), and Aqua Pharma (UK, fish health products).
Segment by Type (Product Category):
- Water Disinfectants – Largest segment (approx. 30% of market). Includes: chlorine compounds (bleach, chlorine dioxide), iodine products (iodophors, PVP-iodine), hydrogen peroxide, potassium permanganate, formalin, quaternary ammonium compounds. Used for pond bottom sterilization, incoming water treatment, equipment disinfection, and treatment of external bacterial/fungal infections (egg disinfection). China uses many disinfectants prophylactically (weekly).
- Oral Antimicrobials (antibiotics) – Second-largest (approx. 25% of market, declining due to AMR concerns). Approved drugs: oxytetracycline (most common), florfenicol (broader spectrum), sulfadimethoxine/ormetoprim, amoxicillin. Used for bacterial diseases: furunculosis (Aeromonas), columnaris (Flavobacterium), enteric septicemia, vibriosis (shrimp). Withdrawal periods (days to weeks before harvest). Restrictions in US (VFD, veterinary feed directive), EU (prescription only). Asia over-the-counter widely available.
- Parasite Repellents – Third-largest (approx. 20% of market). External parasites: sea lice (salmon – major problem, costing industry $500 million/year), anchor worm (Lernaea), fish lice (Argulus), gill flukes (Dactylogyrus, Gyrodactylus). Treatments: organophosphates (dichlorvos, azamethiphos – declining), pyrethroids (deltamethrin, cypermethrin), hydrogen peroxide, emamectin benzoate (SLICE, in-feed), and mechanical removal (laser, warm water, cleaner fish – wrasse). In-feed SLICE dominant for sea lice in salmon. Traditional in Asia: trichlorfon, copper sulfate (toxic).
- Chinese Herbal Medicine – Fastest-growing segment (approx. 12% of market, CAGR 8.5%). Plant extracts: garlic (allicin) – antibacterial, immune stimulant; cinnamon; astragalus (Huang Qi); isatis root (Ban Lan Gen) – antiviral; Andrographis; Scutellaria. Blended into feed (1-3%). Believed to have fewer residues, less resistance. Strong adoption in China.
- Water Quality Improvers – (approx. 7% of market). Not strictly “medicines” but used to prevent disease. Includes: probiotics (Bacillus, Lactobacillus, Nitrobacter); enzymes; zeolites (ammonia adsorption); sodium thiosulfate (chlorine neutralizer); EDTA (heavy metal chelation); bioremediation bacteria for sludge.
- Biological Products (Vaccines) – (approx. 5% of market, higher % in salmon). Vaccines for salmon (furunculosis, vibriosis, IPN, pancreas disease), tilapia (streptococcus), catfish (ESC). Administered via injection (hand or automated), immersion, or oral (feed). Autogenous vaccines for emerging pathogens.
- Others – Includes hormones (spawning induction – carp pituitary, HCG, LHRHa), anesthetics (MS-222, clove oil, AQUI-S), and diagnostic reagents. Approx. 1%.
Segment by Application:
- Aquatic Animals – Dominant segment (>95% of market). Includes finfish (salmon, trout, tilapia, catfish, carp, sea bass, bream, cobia, tuna), crustaceans (shrimp, prawns, crabs, lobsters), mollusks (oysters, clams, mussels, abalone), and amphibians (frogs).
- Aquatic Plants – Minor segment (<5%). Includes seaweeds (Porphyra/nori, Saccharina/kombu, Undaria/wakame), and freshwater plants (aquarium trades). Algaecides (copper, diuron, endothall) for pond/lake management, not often classified as fishery medicines.
Industry Layering: Fishery Medicine Types by Target
| Category | Primary Use | Administration | Approved Products | Regulatory (US/Europe) | China |
|---|---|---|---|---|---|
| Water disinfectants | Pond prep, disease prevention | Bath (water) | Chlorine, iodine, H2O2, KMnO4, formalin | Some approved (H2O2), others restricted | Widely used OTC |
| Oral antimicrobials | Bacterial disease treatment | In-feed (medicated feed) | Oxytetracycline, florfenicol, sulfa drugs | VFD/prescription required | OTC widely available |
| Parasite repellents | Sea lice, flukes | Bath, in-feed | Emamectin benzoate (SLICE), deltamethrin, azamethiphos | Approved (prescription) | OTC (trichlorfon, copper) |
| Chinese herbal medicine | Immune enhancement, disease prevention | In-feed (blended) | No formal approvals (considered feed additive) | Not recognized (EU, US) | Approved as veterinary drug (some) |
| Water quality improvers | Ammonia/nitrite reduction | Water | Probiotics, zeolites | Not regulated (considered supplements) | Widely used |
| Vaccines | Disease prevention | Injection, immersion | Numerous (salmon, tilapia, trout) | Fully approved biologics | Approved (imported & domestic) |
Technological Challenges & Policy Developments (2025-2026)
- Antimicrobial resistance (AMR) – Global concern. WHO/FDA/OIE promoting responsible use (stewardship). China banned colistin (polymyxin, last-resort antibiotic) in animal feed (2017). Vietnam, Thailand, Indonesia restricting OTC antibiotics. Impact: increasing demand for alternatives (vaccines, probiotics, herbal, water quality management).
- Sea lice resistance – Salmon sea lice (Lepeophtheirus salmonis) resistant to emamectin benzoate (SLICE) after 20+ years use. Alternative treatments: hydrogen peroxide (bath), mechanical removal (laser, warm water, hydrodynamic), cleaner fish (wrasse, lumpfish), skirts (physical barrier), functional feeds (immunostimulants). Resistance management rotating treatments.
- Withdrawal periods and residue testing – Antibiotics must clear fish tissue before harvest (withdrawal period days to weeks). Testing for residues (LC-MS/MS) at processing. Positive residues lead to product destruction, fines. China, Vietnam have lax enforcement; US, EU, Japan test imports for banned substances (chloramphenicol, nitrofurans, malachite green) — high rates of violative shipments.
- Vaccine development challenges – Fish vaccines require adjuvants (oil-based for injection) causing adhesions (peritoneal lesions) affecting welfare. Oral vaccines (feed) less effective (antigens degraded in gut). Immersion vaccines (bath) effective for some pathogens. Lab-to-field transition slow.
Real-World User Case Study (2025-2026 Data):
A tilapia farm in China (120 ponds, annual production 3,000 tons) experienced recurring Streptococcus agalactiae outbreaks (summer, high temp, high stocking density), causing 15-25% mortality in previous years. Antibiotics (florfenicol in-feed) controlled acute mortality but required multiple treatments per season (cost $0.12/kg fish). In 2025, farm adopted integrated disease management: (1) vaccination of fingerlings (immersion streptococcus vaccine, imported from Taiwan, $0.02/fish); (2) reduced use of antibiotics (only for severe outbreaks); (3) probiotic water quality improvers (weekly Bacillus application); (4) Chinese herbal immune stimulant in feed (astragalus + isatis root, 2kg/ton feed). Results (2025 season):
- Streptococcus mortality: reduced from 15-25% to 5-8% (no major outbreak).
- Antibiotic treatments: from 3 per season to 1.
- Vaccine cost: $0.02/fish x 500,000 fingerlings = $10,000.
- Probiotic & herbal cost: $0.03/kg fish x 3,000 tons = $90,000.
- Antibiotic cost savings: ($0.12/kg x 3 treatments = $0.36/kg) reduced to $0.12/kg (1 treatment) — savings $0.24/kg x 3,000 tons = $72,000.
- Mortality reduction savings: 10% reduction (from 20% to 10% of 3,000 tons = 300 tons saved) at $2/kg = $600,000.
- Net benefit: $600,000 + $72,000 = $672,000 – $100,000 (vaccine + herbals) = $572,000 annual benefit. Farm expanded program to all ponds.
Exclusive Industry Outlook (2027–2032):
Three strategic trajectories by 2028:
- Global animal health major tier (Zoetis, HIPRA, Merck Animal Health, Elanco) — 5-6% CAGR. Focus on vaccines, approved antibiotics, parasiticide. R&D intensive, strong regulatory expertise. Premium pricing.
- Asian domestic manufacturer tier (Henan Chuangxin, Bhuvan Biological, many Chinese/Indian producers) — 6-8% CAGR (fastest-growing). Low-cost water disinfectants, Chinese herbal, low- cost antibiotics. Lower regulatory compliance, price competitive.
- Eco-friendly/alternative tier (probiotics, bioremediation, herbal, functional feeds) — 8-10% CAGR. Driven by AMR concerns and consumer demand for “antibiotic-free”, “organic” aquaculture. Higher margins but requires education.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
